• Vivoryon annual report for 2025 highlighted strategic pivot to inflammatory and fibrotic kidney diseases, with lead program varoglutamstat repositioned toward diabetic kidney disease.
• Phase 2 studies VIVIAD, VIVA-MIND missed primary endpoints in early Alzheimer’s disease, prompting discontinuation of Alzheimer’s development.
• Kidney function analyses from both trials showed statistically significant, clinically meaningful eGFR improvement with varoglutamstat versus placebo, supporting planned Phase 2b in stage 3b/4 diabetic kidney disease.
• Pipeline expansion included nomination of next-generation QPCT/L inhibitor VY2149 in preclinical development, with progress dependent on additional funding or partnership.
• Funding actions included Standby Equity Purchase Agreement of up to EUR 15 million signed in April 2025, followed by October 2025 private placement of 3,380,500 shares at EUR 1.5 raising EUR 5.1 million gross.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivoryon Therapeutics NV published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.